Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer

Wei Wei; Michael J Birrer

doi:10.1016/j.ccell.2015.06.008

Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer

Cancer Cell. 2015 Jul 13;28(1):7-9. doi: 10.1016/j.ccell.2015.06.008.

Authors

Wei Wei¹, Michael J Birrer²

Affiliations

¹ Center for Cancer Research, The Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
² Center for Cancer Research, The Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Electronic address: mbirrer@partners.org.

PMID: 26175410
DOI: 10.1016/j.ccell.2015.06.008

Abstract

Adaptive chemoresistance and consequent tumor recurrence present major obstacles to the improvement of the prognosis and quality-of-life of patients with advanced-stage ovarian cancer. In this issue of Cancer Cell, Yu and colleagues describe the critical role of spleen tyrosine kinase (SYK) in paclitaxel resistance by modulating the stability of microtubules.

Publication types

Comment

MeSH terms

Drug Resistance, Neoplasm / drug effects*
Female
Humans
Intracellular Signaling Peptides and Proteins / antagonists & inhibitors*
Microtubules / drug effects*
Ovarian Neoplasms / drug therapy*
Oxazines / administration & dosage*
Paclitaxel / administration & dosage*
Protein-Tyrosine Kinases / antagonists & inhibitors*
Pyridines / administration & dosage*

Substances

Intracellular Signaling Peptides and Proteins
Oxazines
Pyridines
Protein-Tyrosine Kinases
Paclitaxel